AU2021340733A1 - Bioerodible ocular drug delivery insert and therapeutic method - Google Patents

Bioerodible ocular drug delivery insert and therapeutic method Download PDF

Info

Publication number
AU2021340733A1
AU2021340733A1 AU2021340733A AU2021340733A AU2021340733A1 AU 2021340733 A1 AU2021340733 A1 AU 2021340733A1 AU 2021340733 A AU2021340733 A AU 2021340733A AU 2021340733 A AU2021340733 A AU 2021340733A AU 2021340733 A1 AU2021340733 A1 AU 2021340733A1
Authority
AU
Australia
Prior art keywords
insert
pva
hydrolyzed
day
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021340733A
Other languages
English (en)
Other versions
AU2021340733A9 (en
Inventor
Jianbing Chen
Michelle Howard-Sparks
Basel KARZOUN
Dario PAGGIARINO
Said Saim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EyePoint Inc
Original Assignee
Eyepoint Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyepoint Pharmaceuticals Inc filed Critical Eyepoint Pharmaceuticals Inc
Publication of AU2021340733A1 publication Critical patent/AU2021340733A1/en
Publication of AU2021340733A9 publication Critical patent/AU2021340733A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021340733A 2020-09-14 2021-09-13 Bioerodible ocular drug delivery insert and therapeutic method Pending AU2021340733A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063078265P 2020-09-14 2020-09-14
US63/078,265 2020-09-14
US202163176430P 2021-04-19 2021-04-19
US63/176,430 2021-04-19
US202163190052P 2021-05-18 2021-05-18
US63/190,052 2021-05-18
PCT/US2021/050085 WO2022056392A1 (en) 2020-09-14 2021-09-13 Bioerodible ocular drug delivery insert and therapeutic method

Publications (2)

Publication Number Publication Date
AU2021340733A1 true AU2021340733A1 (en) 2023-05-18
AU2021340733A9 AU2021340733A9 (en) 2024-04-18

Family

ID=80629914

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021340733A Pending AU2021340733A1 (en) 2020-09-14 2021-09-13 Bioerodible ocular drug delivery insert and therapeutic method

Country Status (19)

Country Link
US (3) US12551368B2 (enExample)
EP (2) EP4696325A3 (enExample)
JP (1) JP7848190B2 (enExample)
KR (1) KR20230067641A (enExample)
CN (2) CN115531352B (enExample)
AU (1) AU2021340733A1 (enExample)
BR (1) BR112023004677A2 (enExample)
CA (1) CA3191463A1 (enExample)
DK (1) DK4210682T3 (enExample)
FI (1) FI4210682T3 (enExample)
HR (1) HRP20260727T1 (enExample)
IL (1) IL301227A (enExample)
LT (1) LT4210682T (enExample)
MX (1) MX2023002902A (enExample)
PT (1) PT4210682T (enExample)
RS (1) RS68167B1 (enExample)
SI (1) SI4210682T1 (enExample)
SM (1) SMT202600235T1 (enExample)
WO (1) WO2022056392A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067882A1 (en) 2016-10-05 2018-04-12 Titan Pharmaceuticals, Inc. Implantable devices for drug delivery with reduced burst release
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
SI4210682T1 (sl) * 2020-09-14 2026-07-31 EyePoint, Inc. Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
IL315331A (en) * 2022-03-11 2024-10-01 Eyepoint Pharmaceuticals Inc A method of preventing age-related ocular degeneration by providing a drug entry mechanism into the eye
US20250186398A1 (en) * 2022-03-11 2025-06-12 EyePoint Pharmaceuticals, Inc. Continuous dosing regimen for treatment of a condition of the eye
TW202345804A (zh) * 2022-03-11 2023-12-01 美商視點製藥有限公司 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法
US20240024093A1 (en) 2022-07-22 2024-01-25 SpyGlass Pharma, Inc. Intraocular drug delivery systems and methods of use
JP2025525881A (ja) * 2022-08-16 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼内使用するためのニンテダニブの医薬製剤
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121568687A (zh) 2023-04-27 2026-02-24 艾博莱特克斯有限公司 包含聚乙烯醇的弹性体基质
KR102618788B1 (ko) * 2023-06-19 2023-12-28 국민대학교산학협력단 알티라티닙 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 안질환 예방 또는 치료용 약학 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
DK1592407T3 (da) * 2003-01-24 2010-04-19 Psivida Inc Indretning med depotvirkning og fremgangsmåde til okulær indgivelse af carbonanhydraseinhibitorer
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008033562A2 (en) 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds
CN101679356A (zh) 2007-04-05 2010-03-24 辉瑞产品公司 适用于治疗哺乳动物异常细胞生长的6-[2-（甲基-氨甲酰基）苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US20110238036A1 (en) 2009-12-23 2011-09-29 Psivida Us, Inc. Sustained release delivery devices
CA2848397C (en) * 2011-09-14 2022-04-26 Forsight Vision5, Inc. Ocular insert apparatus and methods
WO2013071264A1 (en) 2011-11-11 2013-05-16 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US20160317438A1 (en) 2015-04-29 2016-11-03 Psivida Us, Inc. Injectable sustained release intraocular device
AU2016361579B2 (en) 2015-11-25 2022-08-04 Incept, Llc Shape changing drug delivery devices and methods
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
SG11201901962QA (en) 2016-09-29 2019-04-29 Equinox Sciences Llc Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
EP3570888A1 (en) * 2017-03-03 2019-11-27 MacRegen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
CA3066437A1 (en) * 2017-06-13 2018-12-20 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
CN112165923B (zh) * 2018-04-19 2023-07-21 埃弗拉兹疗法有限公司 用于将物质注射到身体组织或器官的夹层中的装置
WO2020177678A1 (zh) * 2019-03-04 2020-09-10 江苏恒瑞医药股份有限公司 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途
SI4210682T1 (sl) * 2020-09-14 2026-07-31 EyePoint, Inc. Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda
US20250186398A1 (en) * 2022-03-11 2025-06-12 EyePoint Pharmaceuticals, Inc. Continuous dosing regimen for treatment of a condition of the eye

Also Published As

Publication number Publication date
CN115243682A (zh) 2022-10-25
DK4210682T3 (da) 2026-06-08
US20260151260A1 (en) 2026-06-04
EP4210682B1 (en) 2026-03-25
PT4210682T (pt) 2026-05-27
RS68167B1 (sr) 2026-06-30
FI4210682T3 (fi) 2026-05-28
HRP20260727T1 (hr) 2026-07-31
JP2023541056A (ja) 2023-09-27
US20260191682A1 (en) 2026-07-09
CN115531352A (zh) 2022-12-30
EP4696325A3 (en) 2026-05-06
MX2023002902A (es) 2023-04-05
CN115531352B (zh) 2025-04-25
KR20230067641A (ko) 2023-05-16
JP7848190B2 (ja) 2026-04-20
US20220168142A1 (en) 2022-06-02
WO2022056392A1 (en) 2022-03-17
EP4696325A2 (en) 2026-02-18
SMT202600235T1 (it) 2026-07-16
IL301227A (en) 2023-05-01
SI4210682T1 (sl) 2026-07-31
AU2021340733A9 (en) 2024-04-18
BR112023004677A2 (pt) 2023-05-09
CA3191463A1 (en) 2022-03-17
US12551368B2 (en) 2026-02-17
LT4210682T (lt) 2026-06-10
EP4210682A1 (en) 2023-07-19
EP4210682A4 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
US12551368B2 (en) Bioerodible ocular drug delivery insert and therapeutic method
US20150133546A1 (en) Sustained release delivery of one or more agents
US20250186398A1 (en) Continuous dosing regimen for treatment of a condition of the eye
US20250205152A1 (en) Method of preventing age-related macular degeneration by administering an ocular drug delivery insert
US20260083727A1 (en) Pharmaceutical formulations of nintedanib for intraocular use
TWI911436B (zh) 生物可侵蝕之眼用藥物遞送插入物及治療方法
HK40073855A (en) Bioerodible ocular drug delivery insert and therapeutic method
US20250186336A1 (en) Method of treating wet age-related macular degeneration
HK40118703A (en) Method of treating wet age-related macular degeneration
HK40118701A (en) Continuous dosing regimen for treatment of a condition of the eye
CN118891040A (zh) 治疗湿性年龄相关性黄斑变性的方法
CN118871106A (zh) 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法

Legal Events

Date Code Title Description
SREP Specification republished
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ SAIM, SAID; HOWARD-SPARKS, MICHELLE; PAGGIARINO, DARIO; KARZOUN, BASEL AND CHEN, JIANBING